Division of Internal Medicine, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola-Malpighi, Italy.
Curr Pharm Des. 2012;18(15):2236-52. doi: 10.2174/138161212800099892.
Contrast-enhanced ultrasonography (CEUS), providing relevant informations not available with non-enhanced ultrasonography, greatly impacted the practice of liver imaging. The characterization of focal liver lesions (FLLs), is obtained in a rapid, accurate and safe way and is considered the main hepatic indication; however CEUS offers other established or emergent relevant applications. Metastases detection and assessment of response to locoregional tumor treatment are accepted applications with specific indications. Needle guidance in case of poorly or non visible target lesions at conventional ultrasound is also accepted. The early assessment of response to systemic treatment, and in particular to antiangiogenic ones, by quantification software is an emergent application. The manageability of CEUS determined also its use in the operating theatre, improving the accuracy of intraoperatory US with a significant impact on final surgical strategy. In cirrhotic patients, the role of CEUS was proven highly accurate and sensitive in the characterization of portal vein thrombosis, by identification of contrast arterial enhancement inside the thrombus, that occurs only in case of neoplastic origin. In recent years microbubbles taken up by Kupffer cells, thus possessing a "postvascular" phase, were registered as ultrasound contrast agent in Japan (Sonazoid). During the post-vascular phase tumoral tissue tend to appear as a contrast defect image due to the lack of Kupffer cells, strongly contributing to tumor staging beside characterization. Newly developed techniques, such as fusion imaging or real-time three dimensional US, in addition to other applications of CEUS, in terms of post-transplantation or cholecystitis-related complications, have been recently proposed and will be discussed.
超声造影(CEUS)通过提供常规超声无法提供的相关信息,极大地改变了肝脏影像学的实践。快速、准确和安全地对肝脏局灶性病变(FLL)进行特征描述,被认为是其主要的肝脏适应证;但 CEUS 还提供了其他已确立或新兴的相关应用。转移灶的检测和局部肿瘤治疗反应的评估是具有特定适应证的公认应用。在常规超声下难以或无法观察到目标病变时,也可以进行超声引导下的针吸活检。通过定量软件对全身治疗(尤其是抗血管生成治疗)的早期反应进行评估是一项新兴的应用。CEUS 的可管理性也决定了其在手术室中的应用,通过提高术中超声的准确性,对最终手术策略产生重大影响。在肝硬化患者中,CEUS 在门静脉血栓形成的特征描述中具有高度的准确性和敏感性,通过识别血栓内的对比增强动脉,这仅发生在肿瘤起源的情况下。近年来,被库普弗细胞摄取的微泡,因此具有“血管后”相,在日本被注册为超声造影剂(声诺维)。在血管后相,由于缺乏库普弗细胞,肿瘤组织往往表现为对比缺损图像,这对肿瘤分期除特征描述外有很大的贡献。新开发的技术,如融合成像或实时三维超声,以及 CEUS 的其他应用,如在移植后或胆囊炎相关并发症方面,最近已经被提出,并将进行讨论。